Cost Effectiveness Analysis of Eribulin Mesylate (Halaven®) as a Treatment for Metastatic Breast Cancer in Mexico
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.268
https://www.valueinhealthjournal.com/article/S1098-3015(15)02344-X/fulltext
Title :
Cost Effectiveness Analysis of Eribulin Mesylate (Halaven®) as a Treatment for Metastatic Breast Cancer in Mexico
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02344-X&doi=10.1016/j.jval.2015.09.268
First page :
A822
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2488